Stovek

Meloxigekt 2%-TRV

Description:

Meloxigekt 2%-TRV is an anti-inflammatory veterinary product.

Dosage form: solution for injection.

Composition:

1 ml contains 20 mg of meloxicam, excipients (propylene glycol, polyvinylpyrrolidone, dimethylacetamide, hydrochloric acid, sodium hydroxide, methylparaben, propylparaben) and solvent (water for injection).

Indications for use:

The drug is used for cattle and small cattle, horses and pigs as an anti-inflammatory, analgesic and antipyretic agent for acute inflammatory processes (soft tissues, musculoskeletal system, etc.), feverish conditions, and also to relieve pain of various etiologies.

The drug is intended for symptomatic therapy, reduction of pain and inflammation at the time of use, and does not affect the progression of the disease.

Method of administration and dosage:

The drug is used for cattle and small cattle, horses and pigs as an anti-inflammatory, analgesic and antipyretic agent for acute inflammatory processes (soft tissues, musculoskeletal system, etc.), feverish conditions, and also to relieve pain of various etiologies. The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease.

The drug is used once:

Cattle

subcutaneously or intramuscularly at a dose of 2.5 ml per 100 kg of animal body weight;

Horses

intramuscularly at a dose of 3.0 ml per 100 kg of animal body weight;

Pigs

intramuscularly at the base of the ear at a dose of 0.2 ml per 10 kg of the animal's body weight.

The injection volume should not exceed 10 ml per site. If necessary, the drug is administered again after 24 hours.

Pharmaceutical properties

Meloxicam, which is part of the drug, belongs to the non-steroidal anti-inflammatory drugs of the oxicam class (an enolic acid derivative), and has a pronounced anti-inflammatory, analgesic and antipyretic effect.

The mechanism of action consists of selective inhibition of the enzyme cyclooxygenase (COX) and suppression of the synthesis of prostaglandins (inflammatory mediators). Meloxicam inhibits primarily cyclooxygenase-II, providing anti-inflammatory and antipyretic effects, and has little effect on cyclooxygenase-I, minimizing the development of side effects such as bleeding, ulceration and renal dysfunction.

The drug is completely absorbed after parenteral administration. Bioavailability after intramuscular administration is close to 100%. After intramuscular administration of the drug, the maximum concentration of meloxicam is created in the blood after 60-90 minutes and is maintained at a therapeutic level for up to 24 hours.

The drug is metabolized in the liver. It is excreted equally in feces and urine, mainly as metabolites. Less than 5% of the daily dose is excreted unchanged in feces, and only trace amounts of the drug are found unchanged in urine. The average half-life is 20 hours.